References
- World Health Organization. Obesity and overweight. June 9, 2021. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
- Pottegård A, Andersen JH, Søndergaard J, Thomsen RW, Vilsbøll T. Changes in the use of glucose-lowering drugs: a Danish nationwide study. Diabetes Obes Metab. 2023;1‐9. doi:10.1111/dom.14947
- Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi:10.2337/dci22-0034
- Andreasen CR, Andersen A, Vilsbøll T. The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. Diabetologia. 2023;66(10):1846–1858. doi:10.1007/s00125-023-05966-9
- Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201–223. doi:10.1038/s41573-021-00337-8
- Marx N, Federici M, Schütt K, et al. ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–4140. doi:10.1093/eurheartj/ehad192
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi:10.1056/NEJMoa1603827
- Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130. doi:10.1016/s0140-6736(19)31149-3
- Marso SP, Bain SC, Consoli A, et al. SUSTAIN-6 investigators. semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi:10.1056/NEJMoa1607141
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. SELECT trial investigators. semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563
- European Medicines Agency. Shortage of Ozempic. October 19, 2022. https://www.ema.europa.eu/en/documents/shortage/ozempic-semaglutide-supply-shortage_en.pdf.
- Diabetes UK Ozempic and weight loss: the facts behind the headlines. July 5, 2023. https://www.diabetes.org.uk/about_us/news/ozempic-and-weight-loss-facts-behind-headlines.
- ‘You forget to eat’: how ozempic went from diabetes medicine to blockbuster diet drug. National Public Radio (NPR), Washington, D.C. USA. April 1, 2023. https://www.npr.org/2023/04/01/1166781510/ozempic-weight-loss-drug-big-business.
- Awan O. The ozempic craze is sending the wrong public health message. Forbes magazine. July 5, 2023. https://www.forbes.com/sites/omerawan/2023/07/05/the-ozempic-craze-is-sending-the-wrong-public-health-message/.
- Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: the Danish national prescription registry. Int J Epidemiol. 2017;46(3):798. doi:10.1093/ije/dyw213
- Danish Medicines Agency. No general reimbursement for wegovy [in Danish]. July 1, 2022. https://laegemiddelstyrelsen.dk/da/soeg/~/media/64ADE64831734B8CACEB40A476DE5B45.ashx.
- TV2 News. Danish Regions expect explosive increase in subsidies for expensive drugs: scary, expert says [in Danish]. August 9, 2023. https://nyheder.tv2.dk/samfund/2023-08-08-regioner-forventer-eksplosiv-stigning-i-tilskud-til-dyr-medicin-skraemmende-siger-ekspert.
- Danish Health Data Authority. medstat.dk.
- Schmidt M, Schmidt SAJ, Adelborg K, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563–591. doi:10.2147/CLEP.S179083
- Iannone A, Natale P, Palmer SC, et al. Clinical outcomes associated with drugs for obesity and overweight: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023;25(9):2535–2544. doi:10.1111/dom
- Nicolaisen SK, Pedersen L, Witte DR, Sørensen HT, Thomsen RW. HbA1c-defined prediabetes and progression to type 2 diabetes in Denmark: a population-based study based on routine clinical care laboratory data. Diabetes Res Clin Pract. 2023;203:110829. doi:10.1016/j.diabres.2023.110829
- Danish Endocrine Society (DES)/The Danish College of General Practitioners (DSAM). Type 2 diabetes guidelines [Retningslinjer for den farmakologiske behandling af type 2-diabetes]. https://vejledninger.dsam.dk/fbv-t2dm/. Accessed April 15, 2024
- Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251–1261. doi:10.1007/s00125-022-05715-4
- Tan B, Pan XH, Chew HSJ, et al. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Int J Obes. 2023;47(8):677–685. doi:10.1038/s41366-023-01321-5
- European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro. Accessed April 15, 2024
- Ruiz PL, Karlstad Ø, Nøkleby K, et al. Pharmacological treatment of obesity in adults in Norway 2004-2022. Diabetes Obes Metab. 2024. doi:10.1111/dom.15515
- Schramm S, Bramming M, Davidsen M, Rosendahl H, Tolstrup J Burden of disease in Denmark: risk factors [in Danish]. 2023. https://sundhedsstyrelsen.dk/-/media/Udgivelser/2023/Sygdomsbyrden-2023/Risikofaktorer-Sygdomsbyrden-2023.ashx. Accessed April 15, 2024
- World Health Organization European Regional Obesity Report 2022. Copenhagen: World Health Organization Regional Office for Europe; 2022.
- National Center for Health Statistics (U.S.). https://www.cdc.gov/nchs/data/nhsr/nhsr158-508.pdf. Accessed April 15, 2024
- Danish Diabetes Association. https://www.diabetestal.nu/. Accessed April 15, 2024
- Centers for Disease Control and Prevention. National diabetes statistics report website. https://www.cdc.gov/diabetes/data/statistics-report/index.html. Accessed April 15, 2024
- LeBlanc ES, Patnode CD, Webber EM, Redmond N, Rushkin M, O’Connor EA. Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the us preventive services task force. JAMA. 2018;320(11):1172–1191. doi:10.1001/jama.2018.7777
- Puhl RM, Heuer CA. Obesity stigma: important considerations for public health. Am J Public Health. 2010;100(6):1019–1028. doi:10.2105/AJPH.2009.159491
- Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183.
- Allen T, Gyrd-Hansen D, Kristensen SR, Oxholm AS, Pedersen LB, Pezzino M. Physicians under pressure: evidence from antibiotics prescribing in England. Med Decis Making. 2022;42(3):303–312. doi:10.1177/0272989X211069931
- Danish Health Data Authority. Medications for diabetes and overweight including wegovy flextouch [in Danish]. 2023. https://www.esundhed.dk/Emner/Laegemidler/Laegemidlermodovervaegt. Accessed April 15, 2024
- The Danish National Board of Health. The consumption of GLP-1 receptor agonists for the treatment of diabetes must decrease [In Danish]. 2023. https://www.sst.dk/da/nyheder/2023/Forbruget-af-GLP-1-receptor-agonister-til-behandling-af-diabetes-skal-ned. Accessed April 15, 2024
- Funck KL, Knudsen JS, Hansen TK, Thomsen RW, Grove EL. Real-world use of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study, 2012 to 2019. Diabetes Obes Metab. 2021;23(2):520–529. doi:10.1111/dom.14245
- Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R. Contemporary national patterns of eligibility and use of novel cardioprotective antihyperglycemic agents in type 2 diabetes mellitus. J Am Heart Assoc. 2021;10(e021084). doi:10.1161/JAHA.121.021084
- Danish Medicines Agency. New proposal for subsidy status for diabetes medications submitted for hearing. [In Danish]. https://laegemiddelstyrelsen.dk/da/nyheder/2023/nyt-forslag-til-tilskudsstatus-for-diabetesmedicin-sendes-i-hoering/. Accessed April 15, 2024
- Danish Diabetes Association. The diabetes association is fighting to keep already issued subsidies for GLP-1 analogues. https://diabetes.dk/nyheder/2023/diabetesforeningen-kaemper-for-at-beholde-allerede-udstedte-tilskud-til-glp-1-analoger. Accessed April 15, 2024
- Mannucci E, Silverii GA. Cardiovascular prevention with glucose-lowering drugs in type 2 diabetes: an evidence-based approach to the categories of primary and secondary prevention. Diabetes Obes Metab. 2023;25(12):3435–3443. doi:10.1111/dom.15226
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414. doi:10.1001/jama.2021.3224